CA2411542A1 - Encapsulation of polynucleotides and drugs into targeted liposomes - Google Patents

Encapsulation of polynucleotides and drugs into targeted liposomes Download PDF

Info

Publication number
CA2411542A1
CA2411542A1 CA002411542A CA2411542A CA2411542A1 CA 2411542 A1 CA2411542 A1 CA 2411542A1 CA 002411542 A CA002411542 A CA 002411542A CA 2411542 A CA2411542 A CA 2411542A CA 2411542 A1 CA2411542 A1 CA 2411542A1
Authority
CA
Canada
Prior art keywords
seq
peptide
nls
dna
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002411542A
Other languages
English (en)
French (fr)
Inventor
Teni Boulikas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2411542A1 publication Critical patent/CA2411542A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
CA002411542A 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes Abandoned CA2411542A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21092500P 2000-06-09 2000-06-09
US60/210,925 2000-06-09
PCT/US2001/018657 WO2001093836A2 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes

Publications (1)

Publication Number Publication Date
CA2411542A1 true CA2411542A1 (en) 2001-12-13

Family

ID=22784880

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002411542A Abandoned CA2411542A1 (en) 2000-06-09 2001-06-08 Encapsulation of polynucleotides and drugs into targeted liposomes

Country Status (8)

Country Link
EP (1) EP1292284A2 (ja)
JP (1) JP2003535832A (ja)
CN (2) CN1254234C (ja)
AU (2) AU7542301A (ja)
CA (1) CA2411542A1 (ja)
MX (1) MXPA02012198A (ja)
TW (1) TWI292324B (ja)
WO (1) WO2001093836A2 (ja)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144561D1 (de) * 2000-06-16 2011-06-16 Serodus As N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide
CA2412513A1 (en) * 2000-06-22 2001-12-27 San Diego State University Foundation Modulators of recombination and methods for producing and using the same
EP1360311B1 (en) * 2000-08-25 2008-04-09 Aventis Pharmaceuticals Inc. Membrane penetrating peptides and uses thereof
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
AU3652602A (en) * 2000-11-15 2002-05-27 Us Gov Health & Human Serv Sol-fusin: use of gp64-6his to catalyze membrane fusion
SE0101702D0 (sv) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
ATE424815T1 (de) 2001-12-03 2009-03-15 Dor Biopharma Inc Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
WO2005000193A2 (en) 2003-06-30 2005-01-06 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
JP2003286198A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp 増殖因子等を提示するタンパク質中空ナノ粒子を用いる治療薬剤
JP2003286199A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp タンパク質中空ナノ粒子を用いる肝臓疾患治療用薬剤
EP1509203B1 (en) 2002-05-15 2016-04-13 California Pacific Medical Center Delivery of nucleic acid-like compounds
WO2004002468A1 (en) 2002-06-26 2004-01-08 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
CA2495913A1 (en) * 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
EP1603535A4 (en) * 2003-03-18 2008-10-15 Ethicon Inc AROMATASE HEMMER DIAGNOSIS AND THERAPY
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
JP4810825B2 (ja) * 2004-12-27 2011-11-09 東洋紡績株式会社 リパーゼ活性測定方法および測定試薬
US20070014841A1 (en) * 2005-02-08 2007-01-18 Denis Martin Pharmaceutical compositions
JP5067733B2 (ja) * 2005-03-09 2012-11-07 国立大学法人北海道大学 目的物質をミトコンドリア内に送達可能な脂質膜構造体
US20090305409A1 (en) * 2005-03-24 2009-12-10 National University Corporation Hokkaido University Liposome Capable of Effective Delivery of Given Substance Into Nucleus
EP1973928A2 (en) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
CN100376680C (zh) * 2005-11-01 2008-03-26 暨南大学 双重靶效应基因嵌合重组体及其构建方法和应用
EP1790657A1 (en) * 2005-11-24 2007-05-30 Technische Universität München pH-switchable transmembrane peptides as stimulators of membrane fusion
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CA3144493A1 (en) 2006-10-03 2008-04-10 Arbutus Biopharma Corporation Lipid containing formulations
CA2668638A1 (en) * 2006-11-07 2008-05-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs
WO2008116032A1 (en) * 2007-03-21 2008-09-25 Effat Emamian Compositions and methods for inhibiting tumor cell growth
WO2009002274A1 (en) * 2007-06-28 2008-12-31 Agency For Science, Technology And Research Cationic peptide for delivering an agent into a cell
JP2009203174A (ja) * 2008-02-26 2009-09-10 Hokkaido Univ タンパク質−リポソーム複合体を含有するイオントフォレーシス用組成物
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
CN102038640B (zh) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
EP2590670B1 (en) 2010-07-06 2017-08-23 GlaxoSmithKline Biologicals SA Methods of raising an immune response by delivery of rna
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
MX2013000164A (es) 2010-07-06 2013-03-05 Novartis Ag Liposomas con lipidos que tienen valor de pka ventajoso para suministro de arn.
HRP20220695T1 (hr) 2010-08-31 2022-07-08 Glaxosmithkline Biologicals Sa Pegilirani liposomi za isporuku rnk kodirane za imunogen
KR102162111B1 (ko) 2010-10-11 2020-10-07 노파르티스 아게 항원 전달 플랫폼
TW201225972A (en) 2010-11-15 2012-07-01 Univ Ramot Dipeptide analogs for treating conditions associated with amyloid fibril formation
JP6158097B2 (ja) 2011-03-18 2017-07-05 デューク・ユニヴァーシティ 炎症を抑制するためのペプチド
US9303063B2 (en) 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
ES2705498T3 (es) 2011-08-31 2019-03-25 Glaxosmithkline Biologicals Sa Liposomas pegilados para administración de ARN que codifica inmunógeno
US9403877B2 (en) 2012-01-24 2016-08-02 Inter-K Pty Limited Peptide agents for cancer therapy
SG11201503020TA (en) 2012-10-29 2015-05-28 Agency Science Tech & Res A novel reagent for gene-drug therapeutics
CN103211762B (zh) * 2013-04-11 2015-01-14 同济大学 诊疗一体化新型杂化胶束及其制备方法
EP3981437A1 (en) 2014-04-23 2022-04-13 ModernaTX, Inc. Nucleic acid vaccines
BR112017006057B1 (pt) * 2014-09-26 2023-11-21 Universidade Estadual Paulista Júlio De Mesquita Filho - Unesp Composição farmacêutica à base de prostaglandina J2 incorporada em sistemas micelares baseados em poloxâmeros para potencialização das atividades analgésica e anti-inflamatória
MX2017015962A (es) 2015-06-10 2018-07-06 Univ Texas Uso de exosomas para el tratamiento de enfermedades.
WO2017070623A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Herpes simplex virus vaccine
EP3458032A4 (en) * 2016-05-16 2019-12-25 The Board of Regents of The University of Texas System CATIONIC AMINO SULFONAMIDE LIPIDS AND AMPHIPHILIC ZWITTERIONIC AMINO LIPIDS
CA3031705A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Treatment of prostate cancer with niraparib
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MX2020001790A (es) 2017-08-25 2020-07-22 Codiak Biosciences Inc Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana.
US10723782B2 (en) 2017-12-28 2020-07-28 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
CN116375774A (zh) * 2017-12-29 2023-07-04 苏州瑞博生物技术股份有限公司 缀合物及其制备方法和用途
KR102101179B1 (ko) * 2019-09-20 2020-05-15 건양대학교 산학협력단 유방암유래 암줄기세포의 선택적 표적치료를 위한 나노복합체 제조방법
KR102164218B1 (ko) * 2019-09-24 2020-10-12 코스맥스 주식회사 피부 흡수 증진을 위한 다중층 양이온성 리포좀 및 이의 제조방법
WO2022045009A1 (ja) * 2020-08-24 2022-03-03 国立大学法人山口大学 流体を追跡するための組成物及び流体の追跡方法
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
CN114762679B (zh) * 2021-01-13 2023-04-07 上海交通大学医学院 一种纳米复合物及其制备方法和用途
CN113406957B (zh) * 2021-05-19 2022-07-08 成都理工大学 基于免疫深度强化学习的移动机器人自主导航方法
CN113546180A (zh) * 2021-05-25 2021-10-26 重庆医科大学 一种具有心肌靶向性的基因递送载体及其制备方法
CN117813387A (zh) * 2021-07-19 2024-04-02 武汉大学 有效递送多聚核苷酸至细胞的成分与方法
EP4230638A1 (en) * 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
CN114632062A (zh) * 2022-03-21 2022-06-17 南京大学 一种用于递送核酸药物的中性脂质体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
FR2754272B1 (fr) * 1996-10-08 1998-11-13 Rhone Poulenc Rorer Sa Procede de preparation de compositions pour le transfert d'acides nucleiques
ZA9811376B (en) * 1997-12-12 1999-06-28 Expression Genetics Inc Biodegradable mixed polymeric micelles for gene delivery

Also Published As

Publication number Publication date
EP1292284A2 (en) 2003-03-19
JP2003535832A (ja) 2003-12-02
TWI292324B (en) 2008-01-11
AU7542301A (en) 2001-12-17
CN1254234C (zh) 2006-05-03
AU2001275423B2 (en) 2007-01-11
CN1981873A (zh) 2007-06-20
WO2001093836A3 (en) 2002-10-03
CN1444472A (zh) 2003-09-24
WO2001093836A2 (en) 2001-12-13
MXPA02012198A (es) 2004-08-19

Similar Documents

Publication Publication Date Title
US9278067B2 (en) Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
AU2001275423B2 (en) Encapsulation of polynucleotides and drugs into targeted liposomes
AU2001275423A1 (en) Encapsulation of polynucleotides and drugs into targeted liposomes
Magar et al. Liposome-based delivery of biological drugs
Ferreira et al. pH-sensitive liposomes for drug delivery in cancer treatment
US7393478B2 (en) Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
JP6137894B2 (ja) リポソーム−エキソソームハイブリッドベシクル及びその調製法
AU2003205049B2 (en) Efficient nucleic acid encapsulation into medium sized liposomes
Nsairat et al. Recent advances in using liposomes for delivery of nucleic acid-based therapeutics
PL199201B1 (pl) Pęcherzyk lipidowy, sposób wytwarzania pęcherzyka lipidowego oraz zastosowanie pęcherzyka lipidowego
Le Saux et al. Interest of extracellular vesicles in regards to lipid nanoparticle based systems for intracellular protein delivery
WO2003057190A1 (en) Efficient nucleic acid encapsulation into medium sized liposomes
Akkewar et al. Liposomes in the targeted gene therapy of cancer: a critical review
STERNBERG liposome-DNA complexes for gene therapy
JP4450656B2 (ja) リポソームからなる遺伝子導入用キャリア
Sharma et al. Liposomes: vesicular system an overview
Kevadiya et al. Delivery of gene editing therapeutics
JP2007166946A (ja) 標的遺伝子の発現を抑制するための組成物
Arpac Overcoming biological barriers by lipid-based nanocarriers
Woodle et al. Liposomal antisense oligonucleotide therapeutics
Narainpersad Mitochondrial localisation and cellular uptake in vitro using novel ‘mitochondriotropic’liposomes.
Mkhwanazi The use of cholesterol-galacto compounds in liver directed gene delivery.
Palmer Development of stabilized plasmid lipid particles as intracellular gene delivery vehicles
MXPA01006862A (en) Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead